- According to a report by the IQVIA Institute for Human Data Science, US screening and monitoring tests for some cancers came to "a near standstill" in early April 2020 as a result of COVID-19-related health care disruptions.
Why this matters
- The COVID-19 pandemic has affected the entire US health care system, including cancer care, directly and indirectly.
- Analysis of data from IQVIA’s medical claims database, which includes >205 million patients, >1.7 billion claims, and 3 billion service records obtained annually.
- Funding: No external funding from industry or government.
- During the week ending April 10 vs the weekly average for February 1-28, procedure rates fell by:
- 90% for colonoscopies;
- 87% for mammograms;
- 83% for Pap smears;
- 60% for PSA tests; and
- 39% for CT scans for lung cancer.
- Overall patient interactions with oncologists declined by 20% through April 3.
- For patients with aggressive tumors or diagnoses at advanced stages, there was "little or no disruption" in oncologist visits in March compared with February.
- For patients with skin or prostate cancer, visit rates declined by 20%-50% in March.
- Claims data often have limited clinical information.